Paper4178641
Modification of Parkinsonism--chronic treatment with L-dopa.
Cotzias GC and 2 others. N Engl J Med, 1969. Cited by 1,249 papers, by iCite.
Cite this record
ConductScience Library. Modification of Parkinsonism--chronic treatment with L-dopa. Papers, record 4178641. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4178641
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics27
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Dihydroxyphenylalanine | Major topic |
| Parkinson Disease | Major topic |
| Adult | |
| Aged | |
| Agranulocytosis | |
| Aromatic Amino Acid Decarboxylase Inhibitors | |
| Blood Urea Nitrogen | |
| Blood-Brain Barrier | |
| Chronic Disease | |
| Dopamine | |
| Feeding and Eating Disorders | |
| Female | |
| Humans | |
| Huntington Disease | |
| Male | |
| Manganese | |
| Mental Processes | |
| Methyldopa | |
| Middle Aged | |
| Movement Disorders | |
| Nausea | |
| Neurologic Manifestations | |
| Phenylacetates | |
| Placebos | |
| Thyroid Function Tests | |
| Tyrosine | |
| Vomiting |
Source PubMed
Cited by306
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,249 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42965636 | Subcutaneous apomorphine and the nonmotor features of Parkinson's disease. | J Neural Transm (Vienna) | 2026 | https://conductscience.org/library/papers/42965636 | PubMed |
| 42869935 | Perspectives on ionizing radiation and Parkinson's disease. | NPJ Parkinsons Dis | 2026 | https://conductscience.org/library/papers/42869935 | PubMed |
| 42646502 | Parkinson's Disease: Pathophysiology, Treatment Strategies, Wellness Approaches, and Obstacles/Paths Forward. | NeuroSci | 2026 | https://conductscience.org/library/papers/42646502 | PubMed |
| 42449370 | Parkinson's disease as a multi-axis systems disorder: integrating molecular pathology and circuit-level therapeutics. | Cell Commun Signal | 2026 | https://conductscience.org/library/papers/42449370 | PubMed |
| 42393412 | Cardiovascular pharmacology of dopaminergic agents in humans: a review. | Clin Auton Res | 2026 | https://conductscience.org/library/papers/42393412 | PubMed |
| 42205208 | Dopamine 2 receptor ablation from cholinergic neurons attenuates L-DOPA induced dyskinesias. | Front Aging Neurosci | 2026 | https://conductscience.org/library/papers/42205208 | PubMed |
| 42192052 | The Dark Matter of Levodopa Pharmacodynamics. | Mov Disord | 2026 | https://conductscience.org/library/papers/42192052 | PubMed |
| 41854085 | The central cholinergic system as a therapeutic target in Parkinson's disease. | J Parkinsons Dis | 2026 | https://conductscience.org/library/papers/41854085 | PubMed |
| 41269916 | Mucuna pruriens in untreated Parkinson's disease in sub-Saharan Africa: A 12-month, multicenter, randomized, controlled trial. | J Parkinsons Dis | 2026 | https://conductscience.org/library/papers/41269916 | PubMed |
| 41192415 | Dopamine production in the central nervous system is important for follicle survival and interacts with genetic background and a high sugar diet during Drosophila oogenesis. | Genetics | 2026 | https://conductscience.org/library/papers/41192415 | PubMed |
| 41142700 | 3D printing in medicine: bridging imaging, education, and practice. | Arch Med Sci Atheroscler Dis | 2025 | https://conductscience.org/library/papers/41142700 | PubMed |
| 41117498 | A PLAN to address the Parkinson pandemic. | J Parkinsons Dis | 2025 | https://conductscience.org/library/papers/41117498 | PubMed |
| 41019763 | Combined molecular characterization and dopa-responsive treatment in two patients with NR4A2-associated intellectual developmental disorder. | Front Genet | 2025 | https://conductscience.org/library/papers/41019763 | PubMed |
| 40808403 | Nigrostriatal dopaminergic vulnerability in Parkinson's disease: Neuroprotective strategies. | Neural Regen Res | 2026 | https://conductscience.org/library/papers/40808403 | PubMed |
| 40679671 | Update on the Present and Future Pharmacologic Treatment of Parkinson's Disease. | Neurol Ther | 2025 | https://conductscience.org/library/papers/40679671 | PubMed |
| 40635563 | Disease-Modifying Trials in Treated Parkinson's Disease: "Stable Treated" Does Not Equate with Biological Stability. | Mov Disord | 2025 | https://conductscience.org/library/papers/40635563 | PubMed |
| 40593919 | Postsynaptic adaptations in direct pathway muscarinic M4-receptor signaling follow the temporal and regional pattern of dopaminergic degeneration. | NPJ Parkinsons Dis | 2025 | https://conductscience.org/library/papers/40593919 | PubMed |
| 40500227 | Striatal Dopamine Actions and Movement: Inferences from Parkinson Disease. | J Neurosci | 2025 | https://conductscience.org/library/papers/40500227 | PubMed |
| 40293707 | L-DOPA Induces Spatially Discrete Changes in Gene Expression in the Forebrain of Mice with a Progressive Loss of Dopaminergic Neurons. | Mol Neurobiol | 2025 | https://conductscience.org/library/papers/40293707 | PubMed |
| 40216783 | Oral health implications in Parkinson's disease. | NPJ Parkinsons Dis | 2025 | https://conductscience.org/library/papers/40216783 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/4178641
GET https://conductscience.org/api/papers/v1/4178641/cited_by?page=2